HER2 mutations can be detected in up to 15%–19% of prostate neuroendocrine tumor and bladder cancer; 3%–6% of colorectal, gastric, and esophageal cancers; and less than 3% in breast and lung cancers (Connell and Doherty, 2017). This evidence concerns the gene ERBB2 and lung carcinoma.